White Paper

Strategies For Ensuring Biomanufacturing Resilience For Biologics


There is consensus among the global health community that long-term collaboration in resilient biomanufacturing capacity and supply chains is needed to ensure the reliable delivery of health technologies such as vaccines, even during crisis conditions. This paper highlights strategies that are essential to achieving this outcome, drawn from the experience of MilliporeSigma during the global pandemic response and looking forward to how governments and the private sector, including profit and not-for-profit private health actors, can most effectively work together to deliver healthcare post-pandemic. The strategies focus on vaccines, monoclonal antibodies, and new modalities manufactured by biotechnology companies and institutes.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene